Pivotal study with vismodegib shows positive results in people with advanced BCC
Genentech, a member of the Roche Group announced that a pivotal Phase II study with vismodegib showed positive results in people with advanced basal cell carcinoma or BCC, for whom surgery is considered inappropriate.
HbA1c had a greater impact on predicting CVD in women, but prediction also improved significantly in men.